BullFrog AI Holdings, Inc., a technology-driven drug development company, has announced the identification of multiple potential therapeutic targets for colorectal cancer, including three novel targets, using its proprietary AI-driven platform, bfLEAP™. These discoveries were made by analyzing The Cancer Genome Atlas with the bfLEAP™ platform. The validation of these targets will be carried out in collaboration with the J. Craig Venter Institute (JCVI), a renowned institution in genomics research.
Using the bfLEAP™ platform, BullFrog AI was able to identify 14 candidates that were significantly over-expressed in tumors compared to healthy tissues. Out of these, three were categorized as novel, having no prior association with colon adenocarcinoma in scientific literature. BullFrog AI’s Chairman and CEO, Vin Singh, emphasized the capabilities of the bfLEAP™ platform in identifying novel drug targets from complex datasets.